IRCT2017091836241N2已完成未知
The study of selective cyclooxygenase-2 inhibitor and non-selective cyclooxygenase inhibitor effect in patients with benign prostatic hyperplasia who are on alpha-blocker drugs and its association with PV, PVR, PSA, LUTS
Deputy of Research of Azad University of Pharmaceutical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50 years 至 no limit（—）
- 性别
- Male
入选标准
- •Men over the age of 50 who have moderate to severe benign prostatic hyperplasia with international prostate symptoms score greater than 8; benign prostate diagnosis; no Liver problem; no active infections; no history of frequent urinary tract infections; no clear malignancy; no stone in the urethra, ureter and bladder; no history of urolithiasis; no prostate transurethral removal; no history of inflammation of the prostate; absence of a microscopy hematuria and advanced; no history of or retention; no history of trauma of the lower back and perineal and urethra; no history of cystoscopy; no history of sexually transmitted infections; no history of pelvic or urological surgery; non diabetic; non-neurological diseases (CNA, Parkinson's disease, MS and lumbar disks); history of congestive heart failure; no history of pelvic radiotherapy; no history of tuberculosis; no renal failure with creatinine higher than 1.3; no history of antidepressants, antihistamines, bronchodilators, diuretics and narcotics in the last 3 months; no history of psychological diseases (such as Schizopherenia, severe depression); lack of experience in the use of effective drugs in the treatment of benign prostatic hypertrophy in the last 3 months, including 5a-alpha-reductates and alpha-blockers, and phosphodiesterase inhibitors; no history of persistent alcohol and caffeine intake; high fluid intake; gastrointestinal ulcer or gastrointestinal bleeding.
- •Exclusion criteria: Patient disagreement; unwillingness to follow up the study program for any reason; sensitivity to the drug and its ingredients? the use of the drug causes patient dissatisfaction; the acute urinary problems so that the person has urinary retention and the condition is so severe that it requires catheterization and surgery; prostate cancer
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Evaluation of selective COX-2 inhibitor for the protection of intestinal mucosal damage in comparison to NSAID in patients with rheumatoid arthritis (Investigation by capsule endoscopy and measurement of biomarkers for rheumatoid arthritis)JPRN-UMIN000002554Osaka University30
已完成
不适用
The clinical effect of Cyclooxygenase (COX)-2 selective inhibitors on pollakisuria and lumbar- abdominal pain in patients with prostate cancer who undergo interstitial seed implantation - Randomized control trialprostate cancerJPRN-UMIN000003649ara Medical University150
进行中（未招募）
1 期
Cyclooxygenase inhibitor therapy in patients with oesophageal adenocarcinoma: A pilot study - CITAEUCTR2005-000988-26-GBPortsmouth Hospitals NHS Trust32
已完成
不适用
Efficacy of the treatment with a COX-2 specific inhibitor celecoxib in osteoarthritic patientsAdvanced osteoarthritisMusculoskeletal DiseasesOsteoarthritis (OA)ISRCTN55717501Hospital de Tortosa Virgen de la Cinta (Spain)30
尚未招募
2 期
Role of Selective Cyclooxygenase-2 Inhibitor in Acute PancreatitisCTRI/2020/10/028188Dr Pramod Kumar Garg